Are You Looking for a Top Momentum Pick? Why Clearside Biomedical, Inc. (CLSD) is a Great ChoiceZacks Investment Research • 01/13/21
Clearside Biomedical Announces First Patients Enrolled in Phase 1/2a Clinical Trial of CLS-AX (axitinib injectable suspension) for the Treatment of Wet AMDGlobeNewsWire • 01/12/21
Clearside Biomedical Announces Pricing of $12 Million Registered Direct OfferingGlobeNewsWire • 01/06/21
Week 1 MDA Breakout Stocks - January 2021: Short-Term Picks To Give You An EdgeSeeking Alpha • 01/02/21
Clearside Biomedical Announces Data Presentations at the American Academy Ophthalmology (AAO) 2020 Annual Meeting and Publication on the Suprachoroidal Injection Procedure in Translational Vision Science and TechnologyGlobeNewsWire • 11/16/20
Clearside Biomedical to Present at the Stifel 2020 Virtual Healthcare ConferenceGlobeNewsWire • 11/11/20
Clearside Biomedical, Inc.(CLSD) CEO George Lasezkay on Q3 2020 Results - Earnings Call TranscriptSeeking Alpha • 11/11/20
Clearside Biomedical Announces Third Quarter 2020 Financial Results and Provides Corporate UpdateGlobeNewsWire • 11/10/20
Clearside Biomedical to Report Third Quarter 2020 Financial Results and Provide Corporate Update on Tuesday, November 10, 2020GlobeNewsWire • 10/30/20
Clearside Biomedical Announces Clinical Data Presentations at The Retina Society 2020 and Publication of XIPERE™ Data in Diabetic Macular Edema in Ophthalmology RetinaGlobeNewsWire • 09/23/20
Clearside Biomedical’s Oncology Licensing Partner Doses First Patient in its Phase 2 Study in Patients with Choroidal Melanoma Using SCS Microinjector® for Suprachoroidal DeliveryGlobeNewsWire • 09/11/20
Clearside Biomedical to Present at the Virtual H.C. Wainwright 22nd Annual Global Investment ConferenceGlobeNewsWire • 09/09/20
Clearside Biomedical’s Licensing Partner Doses First Patient in its Phase 2 Gene Therapy Trial Using SCS Microinjector® for Suprachoroidal DeliveryGlobeNewsWire • 09/09/20
Clearside Biomedical, Inc. (CLSD) CEO George Lasezkay on Q2 2020 Results - Earnings Call TranscriptSeeking Alpha • 08/11/20
Clearside Biomedical Announces Second Quarter 2020 Financial Results and Provides Corporate UpdateGlobeNewsWire • 08/10/20
Clearside Biomedical Announces U.S. FDA Acceptance of Investigational New Drug Application for CLS-AX (axitinib injectable suspension) Administered in Suprachoroidal SpaceGlobeNewsWire • 08/10/20
Clearside Biomedical to Present at the 2020 Wedbush PacGrow Healthcare Virtual ConferenceGlobeNewsWire • 08/04/20
Clearside Biomedical, Inc. (CLSD) May Report Negative Earnings: Know the Trend Ahead of Next Week's ReleaseZacks Investment Research • 08/03/20
Clearside Biomedical to Report Second Quarter 2020 Financial Results and Provide Corporate Update on Monday, August 10, 2020GlobeNewsWire • 07/30/20
Clearside Biomedical, Inc. (CLSD) May Report Negative Earnings: Know the Trend Ahead of Q2 ReleaseZacks Investment Research • 07/29/20
Clearside Biomedical Announces Multiple Presentations at the ASRS 2020 Virtual Annual MeetingGlobeNewsWire • 07/27/20